Jarrod Longcor
2022
In 2022, Jarrod Longcor earned a total compensation of $831.8K as Chief Operating Officer at Cellectar Biosciences, a 7% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $175,320 |
|---|---|
| Option Awards | $206,435 |
| Salary | $450,000 |
| Total | $831,755 |
Longcor received $450K in salary, accounting for 54% of the total pay in 2022.
Longcor also received $175.3K in non-equity incentive plan and $206.4K in option awards.
Rankings
In 2022, Jarrod Longcor's compensation ranked 3,420th out of 5,760 executives tracked by ExecPay. In other words, Longcor earned more than 40.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,420 out of 5,760 | 41st |
Division Manufacturing | 1,936 out of 3,136 | 38th |
Major group Chemicals And Allied Products | 927 out of 1,422 | 35th |
Industry group Drugs | 866 out of 1,323 | 35th |
Industry Pharmaceutical Preparations | 632 out of 969 | 35th |
Source: SEC filing on April 26, 2024.
Longcor's colleagues
We found two more compensation records of executives who worked with Jarrod Longcor at Cellectar Biosciences in 2022.
News
Cellectar Biosciences CEO James Caruso's 2023 pay jumps 34% to $2M
April 26, 2024
Cellectar Biosciences CEO James Caruso's 2021 pay jumps 112% to $2.2M
April 29, 2022
Cellectar Biosciences CEO James Caruso's 2020 pay rises 9% to $1M
May 13, 2021
Cellectar Biosciences CEO James Caruso's 2019 pay jumps 21% to $934K
April 28, 2020
Cellectar Biosciences CEO James Caruso's 2018 pay falls 23% to $770K
April 29, 2019